Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Peginterferon alfa-2b for HFMD
NCT07008755Recruiting
- Sponsor
- Zhengzhou Children's Hospital
- Start
- Jul 2024
- Primary completion
- Oct 2027
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised trial of peginterferon alfa-2b in HIV-associated central nervous system involvement (HAND) (2 arms), sponsored by Zhengzhou Children's Hospital. Primary endpoints: Median time to resolution of fever, Median time to resolution of skin rash and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
HIV-associated central nervous system involvement (HAND)
Beyond the preview
Go deeper on NCT07008755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008755.